95 related articles for article (PubMed ID: 22450752)
1. Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment.
Hsieh JL; Lu CS; Huang CL; Shieh GS; Su BH; Su YC; Lee CH; Chang MY; Wu CL; Shiau AL
Cancer Lett; 2012 Aug; 321(1):36-44. PubMed ID: 22450752
[TBL] [Abstract][Full Text] [Related]
2. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
5. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients.
Kuang P; Zhou C; Li X; Ren S; Li B; Wang Y; Li J; Tang L; Zhang J; Zhao Y
Lung Cancer; 2012 Aug; 77(2):427-32. PubMed ID: 22534668
[TBL] [Abstract][Full Text] [Related]
6. Highly sensitive and selective anticancer effect by conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44.
Quan YH; Kim B; Park JH; Choi Y; Choi YH; Kim HK
Exp Lung Res; 2014 Dec; 40(10):475-84. PubMed ID: 25299431
[TBL] [Abstract][Full Text] [Related]
7. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
Ohara T; Takaoka M; Toyooka S; Tomono Y; Nishikawa T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
Cancer Sci; 2011 Jul; 102(7):1344-9. PubMed ID: 21521416
[TBL] [Abstract][Full Text] [Related]
9. [Examination of resistance of lung adenocarcinoma cells to cisplatin by technetium-99m methoxyisobutyl isonitrile].
Hu S; Hu CP; Liang CH
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1493-8. PubMed ID: 16061030
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
12. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells.
Wang D; Xiang DB; Yang XQ; Chen LS; Li MX; Zhong ZY; Zhang YS
Lung Cancer; 2009 Dec; 66(3):298-304. PubMed ID: 19324449
[TBL] [Abstract][Full Text] [Related]
13. Targeting the invasive phenotype of cisplatin-resistant non-small cell lung cancer cells by a novel histone deacetylase inhibitor.
Zuco V; Cassinelli G; Cossa G; Gatti L; Favini E; Tortoreto M; Cominetti D; Scanziani E; Castiglioni V; Cincinelli R; Giannini G; Zunino F; Zaffaroni N; Lanzi C; Perego P
Biochem Pharmacol; 2015 Mar; 94(2):79-90. PubMed ID: 25600908
[TBL] [Abstract][Full Text] [Related]
14. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice.
Onn A; Isobe T; Itasaka S; Wu W; O'Reilly MS; Ki Hong W; Fidler IJ; Herbst RS
Clin Cancer Res; 2003 Nov; 9(15):5532-9. PubMed ID: 14654533
[TBL] [Abstract][Full Text] [Related]
15. Carbon-ion beam irradiation effectively suppresses migration and invasion of human non-small-cell lung cancer cells.
Akino Y; Teshima T; Kihara A; Kodera-Suzumoto Y; Inaoka M; Higashiyama S; Furusawa Y; Matsuura N
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):475-81. PubMed ID: 19735871
[TBL] [Abstract][Full Text] [Related]
16. Release of bFGF following apoptosis and necrosis in NSCLC cells: effects on chemosensitivity to cisplatin.
Kuhn H; Weser L; Gessner C; Hammerschmidt S; Wirtz H
Oncol Rep; 2005 Sep; 14(3):759-62. PubMed ID: 16077988
[TBL] [Abstract][Full Text] [Related]
17. [Prediction of a non-small cell lung cancer sensitivity to cisplatin and paclitaxel based on the marker genes expression].
Boiarskikh UA; Kondrakhin IuV; Evshin IS; Sharipov RN; Komel'kov AV; Musatkina EA; Chevkina EM; Sukoian MA; Kolpakov FA; Kashkin KN; Filipenko ML
Mol Biol (Mosk); 2011; 45(4):652-61. PubMed ID: 21954597
[TBL] [Abstract][Full Text] [Related]
18. Anticancer effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) against A549 non-small cell lung cancer cell line is related to its anti-invasive activity.
Shibata J; Murakami K; Wierzba K; Aoyagi Y; Hashimoto A; Sano M; Toko T; Yamada Y
Anticancer Res; 2000; 20(5A):3169-76. PubMed ID: 11062739
[TBL] [Abstract][Full Text] [Related]
19. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
[TBL] [Abstract][Full Text] [Related]
20. Combination of Sasa quelpaertensis Nakai leaf extract and cisplatin suppresses the cancer stemness and invasion of human lung cancer cells.
Kim M; Kim YS; Kim KM; Ko HC; Kim SJ; Kim JH; Kim Y
Integr Cancer Ther; 2014 Nov; 13(6):529-40. PubMed ID: 24838270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]